Pancreatic Cancer Research

ResearcherUniversity of Wisconsin–MadisonActive in the last 2 years

Nataliya Volodymyrivna Uboha

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3449-1680; OpenAlex author ID A5022835462. Sources: ClinicalTrials.gov.

Their work

Papers
6 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2017: 1 trial · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 6

  1. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. Co-author DOI 10.1038/s41591-026-04283-z↗
  2. Neoadjuvant Stereotactic Body Radiation Therapy Plus Elective Nodal Irradiation With Concurrent Capecitabine for Patients With Resectable Pancreatic Cancer: Su… Co-author DOI 10.1016/j.prro.2025.01.011↗
  3. Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models. Co-author DOI 10.1126/sciadv.adx2984↗
  4. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  5. A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2020.09.010↗
  6. Editorial About: "A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation fo… First author DOI 10.1245/s10434-019-07737-6↗

Trials 1

  1. Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs Principal investigator NCT02943733↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Frederick Bassetti · 3 shared papers, 2021–2025 · strength 0.51
  2. Sharon Marie Weber · 3 shared papers, 2019–2025 · strength 0.47
  3. David Robert Spigel · 2 shared papers, 2024–2026 · strength 0.37
  4. Sean M. Ronnekleiv‐Kelly · 2 shared papers, 2021–2025 · strength 0.31
  5. Noelle K. LoConte · 2 shared papers, 2021–2025 · strength 0.31
  6. Daniel Erik Abbott · 2 shared papers, 2021–2025 · strength 0.31
  7. Jacob S. Witt · 2 shared papers, 2021–2025 · strength 0.31
  8. Zev A. Wainberg · 1 shared paper, 2026 · strength 0.22
  9. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.22
  10. Anwaar Saeed · 1 shared paper, 2026 · strength 0.22
  11. Nathan Bahary · 1 shared paper, 2026 · strength 0.22
  12. Susanna Varkey Ulahannan · 1 shared paper, 2026 · strength 0.22
  13. Shubham Pant · 1 shared paper, 2026 · strength 0.22
  14. Gulam Abbas Manji · 1 shared paper, 2026 · strength 0.22
  15. Paul E. Oberstein · 1 shared paper, 2026 · strength 0.22
  16. Zachary Scott Morris · 1 shared paper, 2025 · strength 0.20
  17. Randall J. Kimple · 1 shared paper, 2025 · strength 0.20
  18. Amato J. Giaccia · 1 shared paper, 2025 · strength 0.20
  19. Md. Mahfuzur Rahman · 1 shared paper, 2025 · strength 0.20
  20. Jeremy D. Kratz · 1 shared paper, 2025 · strength 0.20
  21. Mustafa M. Basree · 1 shared paper, 2025 · strength 0.20
  22. Syed Nabeel Zafar · 1 shared paper, 2025 · strength 0.20
  23. Patrick Beard Schwartz · 1 shared paper, 2019 · strength 0.16
  24. Michael James Overman · 1 shared paper, 2024 · strength 0.16
  25. Nick Pavlakis · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.